Image 1_Multi-antigen MVA-vectored SARS-CoV-2 vaccine, GEO-CM04S1, induces cross-protective immune responses to ancestral and Omicron variants.tiff

<p>The design focus of the first-generation COVID-19 vaccines was on the use of the SARS-CoV-2 spike (S) protein as the primary vaccine immunogen to induce high levels of neutralizing antibodies. Efficacy was repeatedly disrupted due to the diminished neutralizing capacity of vaccine-induced a...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Amany Elsharkawy (18285577) (author)
مؤلفون آخرون: Shannon Stone (19779228) (author), Anchala Guglani (19779231) (author), Felix Wussow (256275) (author), JD Burleson (22599632) (author), Mary Hauser (22599635) (author), Arban Domi (4506175) (author), Pratima Kumari (13249669) (author), Todd R. Albrecht (22599638) (author), Chinonye Dim (19779237) (author), Mark Newman (805798) (author), Don J. Diamond (7354430) (author), Sreenivasa Rao Oruganti (22599641) (author), Mukesh Kumar (132604) (author)
منشور في: 2025
الموضوعات:
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
الوصف
الملخص:<p>The design focus of the first-generation COVID-19 vaccines was on the use of the SARS-CoV-2 spike (S) protein as the primary vaccine immunogen to induce high levels of neutralizing antibodies. Efficacy was repeatedly disrupted due to the diminished neutralizing capacity of vaccine-induced antibodies against emerging variants. Vaccine candidate GEO-CM04S1 is based on the use of a modified vaccinia Ankara vector (MVA) that co-expresses S and nucleocapsid (N) antigens of the Wuhan-Hu-1 reference strain. It is designed to induce both antibody and T-cell responses to both S and N, with the goal of broadening immune response specificity and function. Herein, we characterized GEO-CM04S1 vaccine induced immune responses and efficacy against the ancestral Wuhan strain B.1 and the Omicron subvariant XBB.1.5 in K18-hACE-2 mouse model. We also tested experimental vaccine candidates that encode either S or N proteins alone and determined their relative levels and immunogenicity and contribution to efficacy. We demonstrated that immune responses induced by GEO-CM04S1 protects against weight loss, upper and lower respiratory tract infection, lung injury and excessive inflammation following intranasal challenge with B.1. We showed that only GEO-CM04S1 maintained full protective efficacy against the Omicron subvariant XBB.1.5. GEO-CM04S1 vaccination reduced viral replication without significant lung damage following XBB.1.5 infection. Despite full protection, no neutralizing antibodies were detected against XBB.1.5 in the sera of GEO-CM04S1-immunized animals, suggesting a critical role of T-cell responses. Using antibody-mediated depletion, we showed that depletion of CD20 cells or CD8<sup>+</sup> T cells did not impact the vaccine protective efficacy whereas depletion of CD4<sup>+</sup> T-cells diminished levels of efficacy. Collectively, our data demonstrate the full cross-variant protective immunity induced by GEO-CM04S1 and that CD4<sup>+</sup> T-cell responses are a major effector element of vaccine protection.</p>